Download
1 / 38
400 likes | 419 Views
Clinical radiobiology - normal tissue and fractionation. Categories of factors determining the severity of normal tissue damage. Controllable factors Refers to total dose and irradiated volume More severe and more likely to occur as the dose is increased
E N D
Categories of factors determining the severity of normal tissue damage • Controllable factors • Refers to total dose and irradiated volume • More severe and more likely to occur as the dose is increased • More frequent as the size of the field increase • Fractionation schedule is important • Uncontrollable factors • Age, clinical status, concurrent disease, genes, lifestyle
Late reactions ~ months to years after treatment start teleangiectasi
Dose response curve The radiosensitivity of individuals is Gaussian distributed Dose response curve
Normal tissue tolerance Theoretical concept – difficult to put into clinical practice
Steepness of dose response curves Is often given for the 37% and/or 50% level A 1% dose increment (D) from a reference dose yields an increase in response equal to percentage points
Gaussian distribution of radiation sensitivity Gaussian distribution of technical and dosimetrical factors Uniquely described by two parameters: - gradient at 50% response level D50% - dose to achieve 50% response biolo > clin Dose response curve Clinical dose response curve Pettersen M et al Radiotherapy and Oncology 2008
Quantification of normal tissue damage A. Visual scoring
Quantification of normal tissue damage B. Assays of tissue function • Example: • Lung function • Urination frequency • Stool frequency • etc.
Strandqvist plot, irradiation of skin Total dose Number of fractions Ellis suggested the following equation (1969): D = NSDN0.24 T0.11 NSD – Nominal standard dose where D is total dose, N is the number of fractions, T is total treatment time
Isoeffect curves • Different tolerance level for various tissue • Late-responding tissue have a steeper curve • Early-responding tissue is less sensitive to changes in fraction size
Mathematical modeling – the LQ-model • Assumption: • The cell is inactivated when both DNA strands are damaged • DSB can be produced a single track or by two close SSBs produced by independent tracks • Both these events are random and rare and can therefore be described by Poisson statistics • The probability of there being no such events, that is, the surviving fraction, S, of cells, is given by: Where p is the mean number of hits per cell
Mathematical modeling – the LQ-model • For single particle events, p is linear function of the dose, D • This means that the mean number of hits per cell can be expressed as α·D, and thus • where α is the average probability per unit dose that such single-particle event will occur
Mathematical modeling – the LQ-model • The mean probability of one particle causing damage in one arm of DNA in any specific cell is linearly proportional to the dose, D, and this will also be the case for the second particle • This means that the probability of both events occurring is D2, so the probability of no such event will be • where β is the mean probability per unit square of the dose
Mathematical modeling – the LQ-model The overall LQ equation for cell survival is therefore: - letal damage - sub-letal damage The cell survival curve is blue and the initial slope is shown in red
Mathematical modeling – the LQ-model Of special interest is the dose at which the log-surviving fraction for -damage equals that for -damage:
/-ratio represents the curviness of the curve The higher the /-ratio – the straighter the curve, such cells exhibits considerable irreparable damage and/or little repair (high and/or low ) Typical for cancer cells and early reacting tissue (high proliferation)
/-ratio represents the curviness of the curve lower /-ratio – larger shoulder and more bending, suchcells exhibitslittle irreparable damage or high capacity of repair (low and/or high ) Typical for late reacting tissue (low proliferation)
Fractionation • By full repair between fractions (at least 6 hours) the should will be repeated • The therapeutic gain will be improved • Late reacting tissue is more sensitive to fractionation
Mathematical modeling – the LQ-model The survival after fractionated treatment will be given by: Where n is the number of fractions
Typical a/b-values for tumour tissue are approx. 10 Gy Sensitivity for fractionation
Sensitivity for fractionation Typical a/b-values for late reacting tissue are around 3 Gy
Sensitivity for fractionation Typical a/b-values for early reacting tissue are around 3 Gy, i.e. the same as tumour tissue
LQ-model Effect = E = -log S S=e-(a•d+b•d2) • n E = (a·d+b·d2)·n = (a+b·d)·D n – number of fractions with dose d, D – total dose TE = E/b = (a/b+d)D BED = E/a = [1+d/(a/b)]·D
2Gy equivalent dose, EQD2 There is a lot of clinical experience where dose per fraction has been 2Gy. Therefore, a non 2 Gy scheme is often expressed in 2Gy equivalent dose, EQD2. TE = (α/β + d)·D (α/β + d)·D = (α/β + 2)·D2Gy
Sensitivity for fractionation Trough fractionation the therapeutic gain can be improved a/b=2-3 a/b=10 Effect per unit dose M. Saunders et al, Lancet Oncology, 2001
Combination of A and D The Universal Survival Curve (USC) Park et al 2008
Fractionation schedules • Conventional fractionation: one treatment per day á 2.0 Gy, 5 days per week • Hyper fractionation: dose per fraction less than 2.0 Gy, for the rest as above • Hypo fractionation: dose per fraction larger than 2.0 Gy, for the rest as above • Accelerated fractionation: Several fractions per day; shorter total treatment time
Fractionation schedules • Some combinations: • Hyper fractionated, accelerated treatment: combination of hyper fractionation and shorter total treatment time • CHART: ’contineous hyper fractionated accelerated radiotherapy’; 3 fractions per day, each fraction had a lower dose than 2.0 Gy. • Concomitant boost: hypo fractionated treatment of GTV, conventional fractionation of CTV. • ...
Fractionation schedules Tumour control Late reactions Hyper fractionation gives a better therapeutic ratio, and thereby allows dose escalation. EORTC hyperfraksjoneringsstudie for pharynx-cancer. Same level of late reactions will occur, while the level of tumour control expects to increase compared to a conventional schedule.
